👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

France delaying EU order for COVID-19 vaccine -Germany's Welt

Published 05/06/2021, 11:03 PM
Updated 05/07/2021, 05:51 AM
© Reuters. FILE PHOTO: A medical worker handles a vial of the Pfizer-BioNTech Covid-19 vaccine at the Korian Samarobriva Ehpad  (care home centre for ederly people) in Amiens, as the spread of the coronavirus disease (COVID-19) continues in France, January 7, 2021.

BERLIN (Reuters) -France is delaying an EU order for 1.8 billion doses of the BioNTech/Pfizer COVID-19 vaccine planned for the next two years, a German newspaper said on Friday, citing EU diplomats, but Paris said it backed the contract and was just asking questions.

In its report, German daily Die Welt said the reason for Paris' hesitation was unclear, but diplomats had speculated that it might want French companies to play a bigger part in vaccine production.

At recent meetings of European Union ministers about vaccine orders, French representatives held up decision-making by posing technical questions and requests for clarifications, Die Welt reported.

Asked about the report, a spokesman for France's Industry Ministry told Reuters: "Contrary to what has been reported, France has officially backed the (vaccine) contract within the formal European Commission framework."

"We are asking common sense questions with regard to the public health challenges we are facing."

Due to massive global demand for booster doses as well as vaccines for young people, EU governments fear that they may be too late and lose out on the order.

© Reuters. FILE PHOTO: A medical worker prepares a dose of the

"That would be a disaster for which France would be responsible," Die Welt quoted one diplomat as saying.

The EU has lagged countries such as Britain and the United States in getting its citizens vaccinated against COVID-19, causing tensions within the 27-nation bloc and prompting criticism of political leaders.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.